Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) rose 12.23% up to $2.05 on no news today; however anticipation of tomorrow’s Q4 financial results is driving the stock.  Oculus will host a conference call tomorrow at 4:30 EST for all shareholders and interested parties. Last week the company announced marketing plans for it’s recently FDA approved Microcyn Technology platform for the irrigation and management of post-surgical wounds. The company has received clearance from health agencies throughout the US, Europe, India, China and Mexico and select Middle East countries. Oculus’ Microcyn Technology has treated over two million patients worldwide and has been used in 30 clinical studies, without any adverse effect.  Based in Petaluma, California, Oculus Innovative Sciences is a biopharmaceutical company which develops, manufactures and markets products based upon Microcyn Technology platform, including formulations designed to significantly reduce the need for antibiotics to fight infections.

Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) jumped 18.70% up to $2.73 on no news. Next week Somaxon’s CEO Richard Pascoe, will participate at the 12th Annual BIO CEO & Investor Conference at the Waldorf-Astoria in New York, Monday, February 8th at 9:30 A.M. In January the sleep drug maker refilled its New Drug Application (NDA) on behalf of Silenor (doxepin) with the FDA, seeking approval for its drug candidate for the treatment of insomnia.  On December 7th 2009, the FDA declined Silenor for the second time that year; the stock spiralled down some 72% by mid-December, where it was trading around $0.928.  Fortunately the clinical safety of the drug was not an issue for the FDA; however the government agency was not satisfied with the efficacy standard for sustained sleep required to maintain effectiveness in adults with insomnia. The review is expected to be completed sometime in mid-March 2010. Headquartered in San Diego, California, Somaxon is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the central nervous system such as insomnia.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Related posts:

1. Sleeper Hit Somaxon Skyrockets On Round Three Of FDA Review Somaxon Pharmaceuticals Inc. up 102.27% on news the sleep drug...
2. Somaxon Pharmaceuticals Inc. (SOMX) Surges On Upcoming FDA Date Somaxon Pharmaceuticals Inc. (NASDAQ:SOMX) surged 49.00% to $4.47, its highest...
3. Biopharmaceutical Gainers With Volume: SNSS, OCLS OCLS up 19.31% to close at $1.73. The company anticipates...
4. Cyclacel Pharmaceuticals Inc. Jumps 152% On Review Of Drug Candidate CYCC skyrocketed 152.17% to close at $2.670 with after hour...
5. GlowWorm Sends CNLG Soaring, KTCC Jumps On Excellent Fiscal Report CNLG up 81.40% to $2.34, trading well above its 200...

Related posts brought to you by Yet Another Related Posts Plugin.